doi:10.1186/s12986-021-00586-9 Mousavi R, Alizadeh M, Asghari Jafarabadi M, et al
Clinical trials show patients lose 1520% of their body weight with semaglutide and even more with dual-action tirzepatide
A theoretical model the serotonin pathway GLP-1 agonists are becoming increasingly significant in the treatment of diseases like diabetes, metabolic syndrome, and obesity, mimicking the action of endogenous GLP-1, an anorectic hormone produced in multiple human body tissues including the intestine, pancreas, and central nervous system [20,21]
Interpretable architecture (or post hoc explainers) can identify the main drivers of recommendations (e.g., SHAP-based feature attributions)
Why is oral glutathione supplementation often ineffective